Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The Cancer Research Collaboration and Breastlink New York Partner With Diabetes Prevention Program Provider Blue Mesa Health


Posted on: 15 Mar 18

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- The Cancer Research Collaboration (CRC), a non-profit organization dedicated to expanding the availability of cutting-edge cancer research, and Breastlink New York, a leader in breast care that provides complete and total care to all of its patients (from initial screening to the successful completion of treatment), which is a division of RadNet, Inc. (Nasdaq:RDNT), a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, are proud to work in conjunction with Blue Mesa Health’s Transform program.

Founded in 2015, Blue Mesa Health has designed and commercialized diabetes prevention programs, Transform and Transformemos, which are based on the Center for Disease Control and Prevention (CDC) landmark National Diabetes Prevention Program. Transform and Transformemos are year-long lifestyle change programs that include remote certified health coaching, a peer support group, online education and connected hardware (bathroom scales and activity trackers) all integrated in a smartphone app.

Dr. Alison Estabrook of Breastlink New York said, “during the last three decades, a growing number of studies appear to show that maintaining a healthy weight and being physically active offer additional improvements in breast cancer survival beyond surgery, radiation, and chemotherapy.”

The Transform program will be provided, free of charge, to Breastlink New York patients who are at risk or cancer survivors who meet the program criteria. The goal of the program is to assist patients over 52 weeks to achieve 5-7% weight loss and 150 minutes of moderate physical activity per week. These are important goals for at-risk patients and breast cancer survivors as maintaining a healthy BMI can reduce the risk of developing breast cancer, the risk of recurrence in survivors and the incidence of chronic conditions such as type 2 diabetes.

For more information about the partnership or the program, visit: newyork.breastlink.com/bluemesa.

About Breastlink New York

Breastlink New York is a comprehensive breast health center offering full-service breast cancer treatment from initial screenings to the successful completion of treatment. Breastlink New York has a multidisciplinary team of oncologists, surgeons, radiologists, psychotherapists, researchers and patient advocates on staff to address the needs of breast cancer patients. For more information, visit https://newyork.breastlink.com.

About Blue Mesa Health

Blue Mesa is a digital therapeutics company with headquarters in New York, NY and Vancouver, BC. Blue Mesa provides a digital therapeutics program in the USA and Canada based on the CDC's landmark National Diabetes Prevention Program. In the United States, employers, health plans, accountable care organizations, hospital systems are recognizing the return on investment provided by culturally tailored and digitally delivered preventive health programs. Blue Mesa has raised Series AA funding from Nimbus Synergies Inc., Pallasite Ventures, Stanley Park Ventures Inc., and publicly traded technology firm Mobio Technologies Inc. and other US investors. For more information, visit www.bluemesahealth.com.

About the Cancer Research Collaboration

The Cancer Research Collaboration (CRC) is a non-profit organization dedicated to expanding the availability of cutting-edge cancer research. CRC assists investigators, pharmaceutical companies, and CROs in identifying new agents and technologies for diagnosis and treatment of diseases. This research includes tumor profiling, molecular imaging, new device development, vaccine strategies and molecular profiling and genomic testing. CRC builds collaborations to foster innovation in research, education and supportive programs aimed at benefitting patients living with cancer or moving beyond it. For more information, visit www.cancerresearchcollaboration.org.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 298 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,300 employees. For more information, visit https://www.radnet.com.

CONTACT: CONTACT:           Curtis Duggan, CEO and Co-Founder press@bluemesahealth.com 1.347.468.3343GlobeNewswire
globenewswire.com

Last updated on: 16/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.